Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in Alzheimer's Disease
NCT05476783Phase 2Terminated
- Sponsor
- TrueBinding Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TB006 in Alzheimer's disease (AD), sponsored by TrueBinding Inc.. Started Sep 2022; status: terminated.
02
Drugs
TB006
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05476783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476783.